CeloNova BioSciences Inc. announced this week that the first patient has been enrolled in its COBRA REDUCE trial. The COBRA REDUCE trial recently received conditional U.S. Food and Drug Administration (FDA) approval and will study the Cobra PzF nanocoated coronary stent (NCS) system in patients at high risk of bleeding.

February 10, 2016 — HeartWare International Inc. and Valtech Cardio Ltd. announced the termination of HeartWare's proposed acquisition of Valtech on January 28.

In a finding that could lead to new drugs to treat heart failure, researchers have uncovered the molecular mechanism that regulates how the heart pumps blood.

February 9, 2016 — Cigna has entered into an outcomes-based contract with the pharmaceutical company Novartis for the drug Entresto, which was approved by the U.S. Food and Drug Administration for the treatment of heart failure with reduced ejection fraction.

Valtech Cardio Ltd. announced that it has received German Neue Untersuchungs und Behandlungsmethoden (NUB) Status 1 approval for the Cardioband Mitral Reconstruction System, its flagship device for addressing mitral regurgitation in heart failure patients.

Mount Sinai Heart is undertaking a three-year study to determine whether a workplace-based lifestyle intervention, accompanied by imaging data, will reduce the prevalence of cardiovascular (CV) disease risk factors related to lifestyle.

Columbia Engineering researchers have shown, for the first time, that electrical stimulation of human heart muscle cells (cardiomyocytes) engineered from human stem cells aids their development and function.

The following are the late-breaking clinical trial presentations presented at the 2016 American College of Cardiology (ACC) meeting April 2-4 in Chicago. The trials below were chosen based on the importance of their contribution to cardiovascular science. Click on the highlighted text to see the articles related to each presentation.

Joint ACC/JACC Late-Breaking Clinical Trials
April 2, 2016, 9 a.m., Main Tent (North Hall B1)

February 9, 2016 — Boston Scientific Corp. announced the Centers for Medicare and Medicaid Services (CMS) will cover percutaneous left atrial appendage (LAA) closure therapy under specific criteria, as outlined in the agency's final National Coverage Determination (NCD). This decision, effective immediately, provides consistent and uniform access to the Watchman LAA closure Device as a non-pharmacological treatment option for stroke risk reduction for appropriate Medicare beneficiaries. 

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now